Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilaprazole versus esomeprazole after successful endoscopic hemostasis for upper gastrointestinal ulcer bleeding
ChiCTR2100044194Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ilaprazole and esomeprazole in upper gastrointestinal bleeding (UGIB) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Rebleeding rate within 72 hours after successful endoscopic hemostasis. Started Jan 2021; status: recruiting.
02
Drugs
ilaprazoleesomeprazole
03
Conditions
upper gastrointestinal bleeding (UGIB)
Beyond the preview
Go deeper on ChiCTR2100044194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044194.